Journal of Clinical Endocrinology & Metabolism, Vol 81, 3312-3317, Copyright © 1996 by Endocrine Society

ARTICLES

Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome--a clinical research center study. GHIS Collaborative Group

PF Backeljauw and LE Underwood
Department of Pediatrics, University of North Carolina, Chapel Hill 27599, USA.

Eight children with GH insensitivity syndrome, five with GH receptor deficiency (Laron syndrome) and three with growth-attenuating antibodies to GH, were treated with recombinant human insulin-like growth factor I (IGF-I) for 24 months (one was treated for 36 months). Their ages at the beginning of therapy ranged from 2-11 yr. The dose of IGF-I ranged between 80-120 micrograms/kg, given sc twice daily. During the first year of treatment, height velocity (HV) improved in each patient (mean pretreatment HV, 4.0 cm/yr; mean of first year, 9.3 cm/yr). HV declined by 33% during the second year (mean HV, 6.2 cm/yr). The third year HV of the one patient so treated was approximately the same as that in the second year. The mean SD score HV before therapy was -2.4 and improved to +3.8 and +0.5 after 1 and 2 yr of therapy, respectively. Increased HV was accompanied by weight gain. IGF-I- related hypoglycemia occurred infrequently and only early in treatment. No adverse changes in biochemical profile were observed. Bone age did not advance more rapidly than chronological age (mean change in bone age, 2.1 yr; mean change in chronological age, 2.2 yr). The growth of the spleen and kidneys (determined by ultrasound) was rapid in the first year of therapy. In the second year, spleen growth slowed to a normal rate in most patients. Kidney growth, however, remained relatively rapid. These results indicate that IGF-I stimulates statural growth for at least 2 yr and confirms that this peptide has the capacity to act through endocrine mechanisms. Prolonged treatment of GH insensitivity syndrome patients shows promise. The stimulation of growth by IGF-I treatment over years needs to be documented, and patients need to be monitored for side-effects.

This article has been cited by other articles:

				C. Camacho-Hubner, S. Rose, M. A. Preece, M. Sleevi, H. L. Storr, F. Miraki-Moud, F. Minuto, J. Frystyk, A. Rogol, G. Allan, et al. Pharmacokinetic Studies of Recombinant Human Insulin-Like Growth Factor I (rhIGF-I)/rhIGF-Binding Protein-3 Complex Administered to Patients with Growth Hormone Insensitivity Syndrome J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1246 - 1253. [Abstract] [Full Text] [PDF]

				Z. Laron Laron Syndrome (Primary Growth Hormone Resistance or Insensitivity): The Personal Experience 1958-2003 J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1031 - 1044. [Abstract] [Full Text] [PDF]

				E. F. Gevers, N. Loveridge, and I. C. A. F. Robinson Bone Marrow Adipocytes: A Neglected Target Tissue for Growth Hormone Endocrinology, October 1, 2002; 143(10): 4065 - 4073. [Abstract] [Full Text] [PDF]

				Z Laron Insulin-like growth factor 1 (IGF-1): a growth hormone Mol. Pathol., October 1, 2001; 54(5): 311 - 316. [Abstract] [Full Text] [PDF]

				K. Sjogren, K. Wallenius, J.-L. Liu, M. Bohlooly-Y, G. Pacini, L. Svensson, J. Tornell, O. G.P. Isaksson, B. Ahren, J.-O. Jansson, et al. Liver-Derived IGF-I is of Importance for Normal Carbohydrate and Lipid Metabolism Diabetes, July 1, 2001; 50(7): 1539 - 1545. [Abstract] [Full Text] [PDF]

				P. F. Backeljauw and L. E. Underwood Therapy for 6.5-7.5 Years with Recombinant Insulin-Like Growth Factor I in Children with Growth Hormone Insensitivity Syndrome: A Clinical Research Center Study J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1504 - 1510. [Abstract] [Full Text]

				K. A. Woods, C. Camacho-Hübner, R. N. Bergman, D. Barter, A. J. L. Clark, and M. O. Savage Effects of Insulin-Like Growth Factor I (IGF-I) Therapy on Body Composition and Insulin Resistance in IGF-I Gene Deletion J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1407 - 1411. [Abstract] [Full Text]

				M. E. Wilson Insulin-Like Growth Factor I (IGF-I) Replacement during Growth Hormone Receptor Antagonism Normalizes Serum IGF-Binding Protein-3 and Markers of Bone Formation in Ovariectomized Rhesus Monkeys J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1557 - 1562. [Abstract] [Full Text]

				The Essential Role of IGF-I: Lessons from the Long-Term Study and Treatment of Children and Adults with Laron Syndrome J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4397 - 4404. [Abstract] [Full Text]

				L. E. Levitt Katz, R. J. Ferry Jr., C. A. Stanley, P. F. Collett-Solberg, L. Baker, and P. Cohen Suppression of Insulin Oversecretion by Subcutaneous Recombinant Human Insulin-Like Growth Factor I in Children with Congenital Hyperinsulinism Due to Defective {beta}-Cell Sulfonylurea Receptor J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3117 - 3124. [Abstract] [Full Text]

				K. Sjogren, J.-L. Liu, K. Blad, S. Skrtic, O. Vidal, V. Wallenius, D. LeRoith, J. Tornell, O. G. P. Isaksson, J.-O. Jansson, et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice PNAS, June 8, 1999; 96(12): 7088 - 7092. [Abstract] [Full Text] [PDF]

				C. Camacho-Hübner, K. A. Woods, F. Miraki-Moud, P. C. Hindmarsh, A. J. Clark, Y. Hansson, A. Johnston, R. C. Baxter, and M. O. Savage Effects of Recombinant Human Insulin-Like Growth Factor I (IGF-I) Therapy on the Growth Hormone-IGF System of a Patient with a Partial IGF-I Gene Deletion J. Clin. Endocrinol. Metab., May 1, 1999; 84(5): 1611 - 1616. [Abstract] [Full Text]

				J. E. Sanchez, E. Perera, L. Baumbach, and W. W. Cleveland Growth Hormone Receptor Mutations in Children with Idiopathic Short Stature J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 4079 - 4083. [Abstract] [Full Text]

				J. L. Walker, P. A. Crock, S. N. Behncken, S. W. Rowlinson, L. M. Nicholson, T. J. C. Boulton, and M. J. Waters A Novel Mutation Affecting the Interdomain Link Region of the Growth Hormone Receptor in a Vietnamese Girl, and Response to Long-Term Treatment with Recombinant Human Insulin-Like Growth Factor-I and Luteinizing Hormone-Releasing Hormone Analogue J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2554 - 2561. [Abstract] [Full Text]

				C. Ohlsson, B.-A. Bengtsson, O. G. P. Isaksson, T. T. Andreassen, and M. C. Slootweg Growth Hormone and Bone Endocr. Rev., February 1, 1998; 19(1): 55 - 79. [Abstract] [Full Text]

				J. Nakae, M. Kato, M. Murashita, N. Shinohara, T. Tajima, and K. Fujieda Long-Term Effect of Recombinant Human Insulin-Like Growth Factor I on Metabolic and Growth Control in a Patient with Leprechaunism J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 542 - 549. [Abstract] [Full Text]

				T. Bianda, Y. Glatz, R. Bouillon, E. R. Froesch, and C. Schmid Effects of Short-Term Insulin-Like Growth Factor-I (IGF-I) or Growth Hormone (GH) Treatment on Bone Metabolism and on Production of 1,25-Dihydroxycholecalciferol in GH-Deficient Adults J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 81 - 87. [Abstract] [Full Text]

				S. Rajaram, D. J. Baylink, and S. Mohan Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions Endocr. Rev., December 1, 1997; 18(6): 801 - 831. [Abstract] [Full Text]

				K. Higaki, Y. Matsumoto, R. Fujimoto, Y. Kurosaki, and T. Kimura Pharmacokinetics of Recombinant Human Insulin-Like Growth Factor-I in Diabetic Rats    Drug Metab. Dispos., November 1, 1997; 25(11): 1324 - 1327. [Abstract] [Full Text]

				D. Le Roith Insulin-Like Growth Factors N. Engl. J. Med., February 27, 1997; 336(9): 633 - 640. [Full Text] [PDF]

				J. Guevara-Aguirre, A. L. Rosenbloom, O. Vasconez, V. Martinez, S. E. Gargosky, L. Allen, and R. G. Rosenfeld Two-Year Treatment of Growth Hormone (GH) Receptor Deficiency with Recombinant Insulin-Like Growth Factor I in 22 Children: Comparison of Two Dosage Levels and to GH-Treated GH Deficiency J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 629 - 633. [Abstract] [Full Text] [PDF]